Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Signed written informed consent prior to any study procedure.

          3. Relapsed and/or refractory multiple myeloma (MM). Subjects must have received at least
             3 prior antimyeloma treatment regimens. Subjects must have documented progressive
             disease during or within 12 months of completing treatment with the last anti-myeloma
             treatment regimen before study entry. Also, subjects with documented evidence of
             progressive disease within the previous 6 months and who are refractory or
             nonresponsive to their most recent anti-myeloma treatment regimen afterwards will be
             also eligible.

             Subjects must have previously received all of the following therapies:

               1. Autologous stem cell transplant

               2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide,
                  pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib),
                  either alone or combination

               3. Anti-CD38 (eg, daratumumab), either alone or combination

          4. Measurable disease

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          6. Adequate organ function

        Exclusion Criteria:

          1. Known active or history of central nervous system (CNS) involvement of MM

          2. Active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS
             (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes)
             syndrome, or clinically significant amyloidosis

          3. Prior treatment with CAR T-cell or another genetically modified T-cell therapy

          4. Prior treatment with investigational therapy directed at BCMA

          5. Uncontrolled or active infection

          6. Active autoimmune disease requiring immunosuppressive therapy

          7. History or presence of clinically significant CNS pathology such as seizure disorder,
             aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar
             disease, organic brain syndrome, or psychosis